Roche reported a 7% increase in group sales at constant exchange rates, driven by strong demand for medicines. The Pharmaceuticals Division saw a 10% sales increase, with top growth drivers including Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus. The Diagnostics Division's sales remained stable, with growth in demand for pathology solutions and blood screening tests offsetting the impact of healthcare pricing reforms in China. Core operating profit increased by 11%, driven by higher sales and effective cost management. Core earnings per share showed significant growth of 12%, and IFRS net income jumped by 23%. Roche confirmed its full-year outlook, expecting an increase in Group sales in the mid single digit range and core earnings per share to develop in the high single digit range. The company received several important approvals, including US approval for Susvimo for diabetic retinopathy and EU approval for Itovebi for advanced breast cancer. Roche also reported positive data on several therapies, including Lunsumio and Polivy combination for blood cancer and Columvi for spinal muscular atrophy. The company advanced four potentially practice-changing therapies into the final phase of clinical development, including NXT007 for haemophilia A and prasinezumab for early-stage Parkinson's disease. Roche's CEO expressed confidence in the company's continued strong momentum and resilience, driven by its innovative on-market portfolio and pipeline.